265 related articles for article (PubMed ID: 28391613)
21. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab.
Kitano S; Tatsuno K; Ishibe J; Shimauchi T; Fujiyama T; Ito T; Ogawa N; Tokura Y
Acta Derm Venereol; 2018 Jul; 98(7):704-705. PubMed ID: 29405244
[No Abstract] [Full Text] [Related]
22. Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide.
Sawamura T; Karashima S; Ohmori A; Sawada K; Kometani M; Takeda Y; Yoneda T
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208612
[TBL] [Abstract][Full Text] [Related]
23. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
24. Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma.
Nakamura Y; Fujino T; Kagamu H; Matsuya T; Teramoto Y; Asami Y; Yamamoto A
JAMA Dermatol; 2017 Aug; 153(8):832-834. PubMed ID: 28492864
[No Abstract] [Full Text] [Related]
25. Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer.
Ohmura H; Kondo M; Uenomachi M; Ariyama H; Ito M; Tsuchihashi K; Ayano M; Niiro H; Akashi K; Baba E
Front Oncol; 2023; 13():1260818. PubMed ID: 37869081
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic syndrome precedes the onset of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome.
Matsunaga T; Izumi Y; Iwanaga N; Kawahara C; Shigemitsu Y; Yoshida S; Kawakami A; Ogawa D; Migita K
Tohoku J Exp Med; 2015 Jan; 235(1):47-52. PubMed ID: 25744363
[TBL] [Abstract][Full Text] [Related]
27. [Vitiligo under checkpoint inhibitors].
Amini-Adle M; Dalle S
Ann Dermatol Venereol; 2018 Oct; 145(10):633-635. PubMed ID: 29866472
[No Abstract] [Full Text] [Related]
28. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
[No Abstract] [Full Text] [Related]
29. Hypopituitarism and hypothyroidism following atrioventricular block during nivolumab treatment.
Oda T; Sawada Y; Okada E; Yamaguchi T; Ohmori S; Haruyama S; Yoshioka M; Nakamura M
J Dermatol; 2017 Jun; 44(6):e144-e145. PubMed ID: 28295551
[No Abstract] [Full Text] [Related]
30. Fundus Hypopigmentation and Loss of Choroidal Nevi Pigmentation Associated With Nivolumab.
Sophie R; Moses GM; Hwang ES; Kim JE
JAMA Ophthalmol; 2019 Jul; 137(7):851-853. PubMed ID: 31070667
[No Abstract] [Full Text] [Related]
31. Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.
Mangana J; Buset CS; Dummer R
JAMA Oncol; 2019 May; 5(5):730-731. PubMed ID: 30676614
[No Abstract] [Full Text] [Related]
32. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid.
Ridpath AV; Rzepka PV; Shearer SM; Scrape SR; Olencki TE; Kaffenberger BH
Int J Dermatol; 2018 Nov; 57(11):1372-1374. PubMed ID: 29624655
[No Abstract] [Full Text] [Related]
33. Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma.
Cinotti E; Fiorani D; Provvidenziale L; Miracco C; Calamai V; Danielli R; Rubegni P
Int J Dermatol; 2019 Jul; 58(7):e138-e140. PubMed ID: 30810218
[No Abstract] [Full Text] [Related]
34. Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.
Gambichler T; Stockfleth E; Susok L
J Immunother Cancer; 2018 Oct; 6(1):113. PubMed ID: 30376886
[TBL] [Abstract][Full Text] [Related]
35. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient.
Arai T; Harada K; Usui Y; Irisawa R; Tsuboi R
J Dermatol; 2017 Aug; 44(8):975-976. PubMed ID: 27649838
[No Abstract] [Full Text] [Related]
36. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
[TBL] [Abstract][Full Text] [Related]
37. Dermoscopic changes in malignant melanoma after successful treatment with nivolumab: A case report.
Yamamura K; Otsuka A; Kaku Y; Seidel JA; Nomura M; Nagai H; Matsumoto S; Kabashima K
J Dermatol; 2017 May; 44(5):547-548. PubMed ID: 27461159
[No Abstract] [Full Text] [Related]
38. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
Numata S; Iwata Y; Okumura R; Arima M; Kobayashi T; Watanabe S; Suzuki K; Horiguchi M; Sugiura K
J Dermatol; 2018 Jan; 45(1):113-114. PubMed ID: 28225147
[No Abstract] [Full Text] [Related]
39. Remitting seronegative symmetrical synovitis with pitting edema: a review.
Lakhmalla M; Dahiya DS; Kichloo A; Fatima T; Edigin E; Wani F
J Investig Med; 2021 Jan; 69(1):86-90. PubMed ID: 33122249
[TBL] [Abstract][Full Text] [Related]
40. [Two cases of RA-like and SLE-like features similar to remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome)].
Yamanishi Y; Taooka Y; Mukuzono H; Aoi K; Ishibe Y; Yamana S
Ryumachi; 1993 Apr; 33(2):162-8. PubMed ID: 8316907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
